NCT03003546View on ClinicalTrials.gov

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Aggressive Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Small Lymphocytic Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER